Priority 15 from the Myeloma (Canada) PSP
| UNCERTAINTY: How can we prevent decline in memory and mental functioning associated with myeloma and its treatment among myeloma patients? (JLA PSP Priority 15) | |
|---|---|
| Overall ranking | 15 |
| JLA question ID | 0113/15 |
| Explanatory note | Both myeloma and its treatment can have adverse effects on memory and cognitive functioning (e.g., "chemo brain"). These challenges can affect patients' relationships, work, and daily living. Participants wanted to know which drugs were associated with these effects, how long the effects will last, and new ways to prevent or manage these issues. |
| Evidence |
No evidence identified |
| Health Research Classification System category | Cancer and neoplasms |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | What effects does myeloma have on mental status. ~ How can the effects of 'chemo-brain' be reduced? ~ Can memory issues be prevented? * Frustration with memory loss and its effects on relationships, work, and tasks for daily living ~ Help with brain fog ~ Effects of high-dose chemotherapy on memory and mental acuity. (Translated from French) ~ Being in my late thirties, does memory come back or will it be permanently affected? (Translated from French) ~ Fatigue and impact on the brain. (Translated from French) |
| Submitted by | Please see the PSP Engagement Summary on the JLA website |
| PSP information | |
|---|---|
| PSP unique ID | 0113 |
| PSP name | Myeloma (Canada) |
| Total number of uncertainties identified by this PSP. | 59 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 28 April 2021 |